<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">43653</article-id><article-id pub-id-type="doi">10.7554/eLife.43653</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-125769"><name><surname>Walens</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126089"><name><surname>DiMarco</surname><given-names>Ashley V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126088"><name><surname>Lupo</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126090"><name><surname>Kroger</surname><given-names>Benjamin R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126091"><name><surname>Damrauer</surname><given-names>Jeffrey S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8148-0285</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-125295"><name><surname>Alvarez</surname><given-names>James V</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2910-7621</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmacology and Cancer Biology</institution>, <institution>Duke University</institution>, <addr-line><named-content content-type="city">Durham</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-124135"><name><surname>Ojala</surname><given-names>Päivi M</given-names></name><role>Reviewing editor</role><aff><institution>University of Helsinki</institution>, <country>Finland</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>andrea.walens@duke.edu</email> (AW);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>james.alvarez@duke.edu</email> (JA);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>04</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e43653</elocation-id><history><date date-type="received"><day>14</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>27</day><month>03</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Walens et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Walens et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-43653-v1.pdf"/><abstract><p>Over half of breast cancer related deaths are due to recurrence five or more years after initial diagnosis and treatment. This latency suggests that a population of residual tumor cells can survive treatment and persist in a dormant state for many years. The role of the microenvironment in regulating the survival and proliferation of residual cells following therapy remains unexplored. Using a conditional mouse model for Her2-driven breast cancer, we identify interactions between residual tumor cells and their microenvironment as critical for promoting tumor recurrence. Her2 downregulation leads to an inflammatory program driven by TNFα/NFκB signaling, which promotes immune cell infiltration in regressing and residual tumors. The cytokine CCL5 is elevated following Her2 downregulation and remains high in residual tumors. CCL5 promotes tumor recurrence by recruiting CCR5-expressing macrophages, which may contribute to collagen deposition in residual tumors. Blocking this TNFα-CCL5-macrophage axis may be efficacious in preventing breast cancer recurrence.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31 CA220957</award-id><principal-award-recipient><name><surname>Walens</surname><given-names>Andrea</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA208042</award-id><principal-award-recipient><name><surname>Alvarez</surname><given-names>James V</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006512</institution-id><institution>Duke University School of Medicine</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Alvarez</surname><given-names>James V</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were performed with approval from the Duke institutional animal care and use committee (IACUC) under Protocol #A199-17-08 and in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.  Mice were housed under barrier conditions with standard 12-hour light/dark hours, and fed standard chow.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Sequencing data have been deposited in SRA as PRJNA506006 for cell line data and PRJNA505845 for macrophage data.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Walens A</collab><collab>DiMarco AV</collab><collab>Kroger BR</collab><collab>Damrauer JS</collab><collab>Lupo R</collab><collab>Alvarez JV</collab></person-group><year iso-8601-date="2018">2018</year><source>Tumor associated macrophage sequencing from primary, regressing, and recurrent MTB;TAN tumors.</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sra">https://www.ncbi.nlm.nih.gov/sra</ext-link><comment>NCBI Sequence Read Archive, PRJNA505845</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Walens A</collab><collab>DiMarco AV</collab><collab>Kroger BR</collab><collab>Damrauer JS</collab><collab>Lupo R</collab><collab>Alvarez JV</collab></person-group><year iso-8601-date="2018">2018</year><source>Changes in gene expression after Her2 down regulation</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sra">https://www.ncbi.nlm.nih.gov/sra</ext-link><comment>NCBI Sequence Read Archive, PRJNA506006</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Creighton CJ</collab><collab>Li X</collab><collab>Landis M</collab><collab>Dixon JM et al</collab></person-group><year iso-8601-date="2009">2009</year><source>Letrozole (Femara) early response to treatment</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10281">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10281</ext-link><comment>NCBI Gene Expression Omnibus, GSE10281</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Stickeler E</collab><collab>Pils D</collab><collab>Klar M</collab><collab>Orlowsk-Volk M et al</collab></person-group><year iso-8601-date="2011">2011</year><source>Molecular Subtype Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21974">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21974</ext-link><comment>NCBI Gene Expression Omnibus, GSE21974</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-43653-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>